{
  "context": {
    "rules": [
      "Rule1: Whenever an outbreak is detected in region1, treatment for disease1 follows.",
      "Rule2: Under the condition that emergency funding is provided for project1, either a vaccine for disease1 is developed or if no outbreak is detected in region1, containment measures are implemented in region1.",
      "Rule3: Emergency funding is provided for project1 or international cooperation is established for project1.",
      "Rule4: Provided that project1 is a government priority, then if international cooperation is established for project1, either a vaccine for disease1 is developed or if no outbreak is detected in region1, containment measures are implemented in region1.",
      "Rule5: Whenever a patent is filed for substance1, intellectual property for substance1 is secured.",
      "Rule6: Under the condition that a legal team is engaged for project1, if intellectual property for substance1 is secured, then financial product1 is not market viable.",
      "Rule7: A legal team is engaged for project1 or patent office cooperation occurs for project1.",
      "Rule8: If patent office cooperation occurs for project1, then provided that intellectual property for substance1 is secured, financial product1 is not market viable.",
      "Rule9: Provided that a commercial partner is identified for project1, then if a technology transfer office is involved in project1, whenever intellectual property for substance1 is secured, financial product1 is not market viable.",
      "Rule10: Under the condition that funding is approved for project1, if a researcher studies region1 for disease1, then findings for disease1 in region1 are published.",
      "Rule11: Whenever market analysis for financial product1 is complete, then if a patent is filed for substance1, financial product1 is not market viable.",
      "Rule12: If investor interest exists for financial product1, then provided that a patent is filed for substance1, financial product1 is not market viable.",
      "Rule13: Under the condition that clinical data for substance1 is strong, regulatory approval is not granted for financial product1.",
      "Rule14: Substance1 is approved or funding is approved for project1.",
      "Rule15: If research team1 is formed, then either clinical trials for substance1 are complete or substance1 is not approved.",
      "Rule16: Research team1 is formed or external collaboration with team1 occurs.",
      "Rule17: Provided that external collaboration with team1 occurs, then either clinical trials for substance1 are complete or substance1 is not approved.",
      "Rule18: Whenever preliminary results for project1 are positive, a grant is secured for project1.",
      "Rule19: Either preliminary results for project1 are positive or a regulatory hurdle exists for project1.",
      "Rule20: If it is not the case that investment secured for project1 implies that if no commercial partner is identified for project1 then manufacturing is planned for substance1, then partnership for project1 does not fail.",
      "Rule21: If it is not the case that either market analysis for financial product1 is complete or investor interest exists for financial product1, then regulatory approval is granted for financial product1.",
      "Rule22: If it is not the case that either market analysis for financial product1 is complete or investor interest exists for financial product1, then clinical data for substance1 is strong.",
      "Rule23: If it is not the case that the negation of a regulatory hurdle for project1 implies treatment for disease1 is available, then funding for project1 is revoked.",
      "Rule24: If it is not the case that the negation of investment secured for project1 implies that if no commercial partner is identified for project1 then manufacturing is planned for substance1, then alternative funding is obtained for project1.",
      "Rule25: If it is not the case that the negation of investment secured for project1 implies that if no commercial partner is identified for project1 then manufacturing is planned for substance1, then alternative funding is not obtained for project1.",
      "Rule26: If no outbreak is detected in region1, then containment measures are not implemented in region1.",
      "Rule27: If treatment for disease1 is not available, then a researcher studies region1 for disease1.",
      "Rule28: If treatment for disease1 is not available, then financial product1 is market viable.",
      "Rule29: If treatment for disease1 is not available, then a patent is filed for substance1."
    ],
    "facts": [
      "Fact1: Project1 is a government priority.",
      "Fact2: A technology transfer office is involved in project1.",
      "Fact3: Investment is secured for project1.",
      "Fact4: It is not the case that project1 is delayed.",
      "Fact5: It is not the case that funding for project1 is revoked.",
      "Fact6: It is not the case that a vaccine for disease1 is developed.",
      "Fact7: It is not the case that findings for disease1 in region1 are published.",
      "Fact8: It is not the case that manufacturing is planned for substance1.",
      "Fact9: It is not the case that clinical trials for substance1 are complete.",
      "Fact10: It is not the case that a grant is secured for project1."
    ]
  },
  "question": "Treatment for disease1 is available."
}